Edition:
United Kingdom

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

2.33USD
16 Aug 2018
Change (% chg)

$0.07 (+3.10%)
Prev Close
$2.26
Open
$2.26
Day's High
$2.35
Day's Low
$2.26
Volume
17,433
Avg. Vol
117,157
52-wk High
$8.61
52-wk Low
$1.41

Latest Key Developments (Source: Significant Developments)

Proteostasis Therapeutics - Co & Astellas Pharma Entered Into Amendment No. 6 To Collaboration & License Agreement
Monday, 23 Apr 2018 

April 23 (Reuters) - Astellas Pharma Inc <4503.T>::PROTEOSTASIS THERAPEUTICS - ON APRIL 20, CO & ASTELLAS PHARMA ENTERED INTO AMENDMENT NO. 6 TO COLLABORATION & LICENSE AGREEMENT DATED NOVEMBER 4, 2014.PROTEOSTASIS THERAPEUTICS SAYS AMENDMENT EXTENDS RESEARCH TERM FOR INITIAL PROJECT UNDER ASTELLAS AGREEMENT TO DEC 4, 2018 - SEC FILING.  Full Article

Proteostasis Therapeutics Prices Public Offering Of 8 Mln Shares At $5/Share
Thursday, 14 Dec 2017 

Dec 13 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 8.00 MILLION COMMON SHARES PRICED AT $5.00PER SHARE.  Full Article

Proteostasis Therapeutics To Sell 7 Mln Shares In Public Offering
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.INTENDS TO OFFER AND SELL, 7 MILLION SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Proteostasis Therapeutics Inc ::PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS.PROTEOSTASIS THERAPEUTICS INC - 28-DAY STUDY CONTINUES TO CONFIRM SAFETY PROFILE OF PTI-428 IN THAT IT WAS GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - PTI-808 WAS FOUND TO BE GENERALLY WELL TOLERATED.PROTEOSTASIS THERAPEUTICS INC - RESULTS OF PTI-428 MEET EFFICACY ENDPOINT IN 28-DAY STUDY IN CF PATIENTS ON BACKGROUND ORKAMBI.  Full Article

Proteostasis Therapeutics Q3 loss per share $0.56
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics reports third quarter 2017 results and provides CF portfolio update.Q3 revenue $1.6 million versus $1.7 million.Qtrly loss per share $0.56 ‍​.  Full Article

Proteostasis Therapeutics to prioritize resources on cystic fibrosis R&D
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - Proteostasis Therapeutics Inc :Proteostasis Therapeutics - ‍initiated strategic prioritization to focus resources on research & development of cystic fibrosis programs, among others​.Proteostasis -‍ as part of the initiative, co is reducing headcount dedicated to research from 46% of total workforce to 34%, by eliminating 13 positions​.Proteostasis Therapeutics - ‍resulting estimated annual cost savings related to prioritization, including personnel & other operating costs, is about $3 million​.Proteostasis Therapeutics Inc - ‍expects to incur a one-time cash charge in Q4 of 2017 for severance and other related costs of $0.2 million​.Proteostasis - ‍restructuring is not anticipated to have operational impact on company's existing cf programs and its UPR program with Astellas​.  Full Article

Proteostasis Therapeutics files to say it is offering 4.3 mln shares of its common stock
Tuesday, 6 Sep 2016 

Proteostasis Therapeutics Inc :Files to say it is offering 4.3 million shares of its common stock.  Full Article

BRIEF-Proteostasis Announces Formation Of Independent Steering Committee To Advise On Global Phase 3 Clinical Development Program For Pti-428 In Cystic Fibrosis

* PROTEOSTASIS ANNOUNCES FORMATION OF INDEPENDENT STEERING COMMITTEE OF LEADING EXPERTS TO ADVISE ON THE GLOBAL PHASE 3 CLINICAL DEVELOPMENT PROGRAM FOR PTI-428 IN CYSTIC FIBROSIS